Researcher:
Aytekin, Saide

Profile Picture
ORCID

Job Title

Doctor

First Name

Saide

Last Name

Aytekin

Name

Name Variants

Aytekin, Saide

Email Address

Birth Date

Filters

2018 - 201912020 - 202210

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.fe5c304d-a410-48bd-b604-9180c95fe942

Search Results

Now showing 1 - 10 of 11
  • Placeholder
    PublicationMetadata only
    Association between lipoprotein (a) level and chronic cardio-renal syndrome in patients with coronary artery disease
    (Wiley, 2021) N/A; N/A; N/A; N/A; N/A; N/A; Ural, Dilek; Cünedioğlu, Berkay Ömer; Yurtseven, Ece; Demiray, Atalay; Aytekin, Saide; Aytekin, Vedat; Faculty Member; Undergraduate Student; Teaching Faculty; Master Student; N/A; Doctor; Faculty Member; School of Medicine; School of Medicine; School of Medicine; Graduate School of Health Sciences; N/A; N/A; School of Medicine; Koç University Hospital; 1057; N/A; 176021; N/A; N/A; 140946
    N/A
  • Placeholder
    PublicationMetadata only
    Assessment of bi-atrial mechanical functions in patients with isolated atrial septal aneurysm
    (Kare Yayıncılık, 2022) N/A; Elçioğlu, Betül Cengiz; Aytekin, Vedat; Aytekin, Saide; Doctor; Faculty Member; Doctor; N/A; School of Medicine; N/A; Koç University Hospital; Koç University Hospital; Koç University Hospital; N/A; 140946; N/A
    N/A
  • Placeholder
    PublicationMetadata only
    Impact of gender and diabetes on the relationship between lipoprotein (a) and coronary artery disease
    (Elsevier Ireland Ltd, 2021) Yurtseven, Ece; Ural, Dilek; Cünedioğlu, Berkay Ömer; Gürsoy, Erol; Güler, Orhan Ulaş; Aytekin, Saide; Aytekin, Vedat; Baysal, Kemal; Teaching Faculty; Faculty Member; Undergraduate Student; Doctor; Undergraduate Student; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; N/A; School of Medicine; School of Medicine; 176021; 1057; N/A; N/A; N/A; N/A; 140946; 119184
    N/A
  • Placeholder
    PublicationMetadata only
    Relationship between lipoprotein (a) and coronary artery disease in patients with very high ldl level
    (Elsevier Ireland Ltd, 2022) Yurtseven, Ece; Ural, Dilek; Cünedioğlu, Berkay Ömer; Gürsoy, Erol; Aytekin, Saide; Aytekin, Vedat; Baysal, Kemal; Teaching Faculty; Faculty Member; Undergraduate Student; Doctor; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; School of Medicine; School of Medicine; 176021; 1057; N/A; N/A; N/A; 140946; 119184
    Background and Aims : Adults who have low density lipoprotein (LDL) cholesterol levels of more than 190 mg/dl are classified in very high-risk group for major cardiovascular events. The data about the impact of Lp(a) on coronary artery disease (CAD) in patients with very high LDL levels is insufficient. We aimed to investigate the relationship of Lp(a) level with CAD in patients with very high LDL levels. Methods: We retrospectively analyzed the data of 247 patients whose LDL levels were equal to or higher than 190mg/dl and who had Lp(a) measurements. Lipid profile, co-morbidities, cardiovascular diseases, blood pressure, body mass index, eGFR and smoking status were assessed. The relationship between Lp(a) levels and CAD was analyzed. Results: A total of 247 patients whose 50.4% were female, 22.6% diabetic and 36.7% hypertensive, 19% had coronary artery disease were included in the analysis. Patients with CAD had higher levels of Lp (a) (median 16 mg/dl vs 23 mg/dl p= 0.024). Age [odds ratio (OR), 1.060; 95% confidence interval (CI): 1.020-1.101; p = 0.003], sex (OR, 6.29; 95% CI:2.604-15.198; p = 0.000) and Lp(a) level (OR, 1.011; 95% CI: 1.001-1.021; p = 0.035) were independently related with CAD. ROC curve analyses demonstrated that Lp(a) level of 19.5mg/dl was the cut-off value for CAD in patients with very high LDL level (AUC:0.6, p=0.023). Conclusions: In our study, we found increased Lp(a) level as a risk factor for CAD in patients with very high LDL levels. Furthermore, our results demonstrate that Lp(a) is the independent predictor of CAD in this patient group.
  • Placeholder
    PublicationMetadata only
    Evaluation of pulmonary arterial stiffness and comparison with right ventricular functions in patients with cirrhosis preparing for liver transplantation
    (Wiley, 2022) Elçioğlu, Betül Cengiz; Baydar, Onur; Helvacı, Füsun; Karataş, Cihan; Aslan, Gamze; Kılıç, Alparslan; Tefik, Nihal; Demir, Barış; Gürsoy, Erol; Demirci, Yasemin; Ural, Dilek; Kanmaz, Turan; Aytekin, Vedat; Aytekin, Saide; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Faculty Member; Faculty Member; Faculty Member; Doctor; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; NA; N/A; N/A; 1057; 275799; 140946; N/A
    Objective Pulmonary complications are common in patients with liver cirrhosis. Devolopment of pulmonary hypertension (PH) is associated with a poor prognosis in these patients. Pulmonary arterial stiffness (PAS) is considered an early sign of pulmonary vascular remodeling. The aim of this study is to investigate PAS and compare it with right ventricular (RV) functions in patients with cirrhosis who are scheduled for liver transplantation. Methods The study included 52 cirrhosis patients (mean age 51.01 +/- 12.18 years, male gender 76.9%) who were prepared for liver transplantation and 59 age and sex matched (mean age 51.28 +/- 13.63 years, male gender 62.7%) healthy individuals. Patients with left ventricular ejection fraction (LVEF) less than 55%, ischemic heart disease, more than mild valvular heart disease, chronic pulmonary disease, congenital heart disease, rheumatic disease, moderate to high echocardiographic PH probability, rhythm or conduction disorders on electrocardiography were excluded from the study. In addition to conventional echocardiographic parameters, PAS value, pulmonary vascular resistance (PVR) and RV ejection efficiency was calculated by the related formulas with transthoracic echocardiography (TTE). Results Demographic characteristics and cardiovascular risk factors of the groups were similar. PAS, PVR, and sPAP values were found to be significantly higher in the patient group (20.52 +/- 6.52 and 13.73 +/- 2.05; 1.43 +/- 0.15 and 1.27 +/- 0.14; 27.69 +/- 3.91 and 23.37 +/- 3.81 p < 0.001, respectively). RV FAC and RV Ee were significantly lower and RV MPI was significantly higher in the patient group (45.31 +/- 3.85 and 49.66 +/- 3.62, p < 0.001; 1.69 +/- 0.35 and 1.85 +/- 0.23, p = 0.005; 0.39 +/- 0.07 and 0.33 +/- 0.09, p = 0.001, respectively). PAS was significantly correlated with RV FAC and MPI (r = -0.423, p < 0.001; r = 0.301, p = 0.001, respectively). Conclusions Increased PAS in cirrhosis patients may be associated with early pulmonary vascular involvement. Evaluation of RV functions is important to determine the prognosis in these patients. FAC, MPI, and RV Ee measurements instead of TAPSE or RV S ' may be more useful in demonstrating subclinical dysfunction. The correlation of PAS with RV FAC and MPI may indicate that RV subclinical dysfunction is associated with early pulmonary vascular remodeling in patients with liver cirrhosis.
  • Placeholder
    PublicationMetadata only
    Evaluation of serum urocortin 2 levels in patients with hypertension
    (Adis Int Ltd, 2020) N/A; N/A; Aslan, Gamze; Aytekin, Saide; Doctor; Doctor; N/A; N/A; Koç University Hospital; N/A; N/A
    Introduction Urocortin 2 (UCN2), is an endogenous stress-related peptide belonging to the corticotropin-releasing factor (CRF) family, has a major role in the pathogenesis of congestive heart failure, ischemic heart disease, and hypertension. Aim To investigate the role of UCN2 levels in patients with hypertension (HTN). Methods Serum UCN2 levels measured by ELISA were compared between patients with HTN (n = 86) and nonHTN (n = 53). Results Eighty-six patients with HTN [median age 66 (45-76); 38 men] and 53 patients with non-HTN [median age 62 (40-80); 39 men] were included into this study. Serum UCN2 (5.17 ng/ml; IQR, 1.26-11.68 ng/ml vs 0.79 ng/ml; IQR, 0.07-4.10 ng/ml, p < 0.0005) levels were found significantly elevated in patients with HTN compared to nonHTN control group. Concentrations of serum UCN2 were positively correlated with left ventricle mass index to body surface area (LV mass index to BSA, r = 0.20, p = 0.03), LV mass index to height(2.7) (r = 0.28, p = 0.002) and body mass index (r = 0.24, p = 0.008). Additionally, logistic regression analysis was performed to UCN2, uric acid, creatinine, glomerular filtration rate, age, body mass index, coronary artery disease and diabetes mellitus which are the potential confounders of hypertension. According to logistic regression analysis serum UCN2 values were found out as an independent predictor of HTN. Conclusion UCN2 levels, correlated with LV mass index were increased in HTN patients compared to nonHTN patients. These data provide evidence that there could be a relationship between high concentrations of UCN2 and HTN. UCN2 may appear as a promising choice of HTN treatment in the future.
  • Placeholder
    PublicationMetadata only
    Gender difference in the relation of serum lipoprotein (a) to reduced renal function in diabetic and non-diabetic patients
    (Elsevier, 2021) Aytekin, Saide; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; Ural, Dilek; Yurtseven, Ece; Cünedioğlu, Berkay Ömer; Güler, Orhan Ulaş; Aytekin, Saide; Aytekin, Vedat; Baysal, Kemal; Faculty Member; Teaching Faculty; Undergraduate Student; N/A; Undergraduate Student; NA; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; 1057; 176021; N/A; N/A; N/A; N/A; 140946; 119184
    N/A
  • Placeholder
    PublicationMetadata only
    Approach to cardiovascular disease in women
    (Turkish Society of Cardiology, 2018) Acar, Rezzan Deniz; Aktoz, Meryem; Atamaner, Oya; Çelik, Hülya Gamze; Çelik, Ömer; Dinçer, İrem; Gazi, Emine; Gülmez, Öykü; N/A; N/A; N/A; Aytekin, Saide; Polat, Evin Bozçalı; Elçioğlu, Betül Cengiz; Doctor; Doctor; Doctor; N/A; N/A; N/A; Koç University Hospita; N/A; 239008; N/A
    Cardiovascular disease (CVD) in women is still not completely understood by either patients or physicians. It is perceived as a health problem that becomes manifest only after menopause; however, it is the most frequent cause of mortality in women and is often seen at an earlier age in the presence of risk factors. Moreover, the symptoms, course, and prognosis are quite different from those seen in men, and both physicians and patients remain inadequately aware of the character of the disease. In the approach to female patients, some risk factors inherent to women should be considered in addition to the classic factors. In this review article, aspects of CVD that are different in women, etiological factors, risk factors specific to women, and particular points to be taken into consideration in the treatment and diagnosis are illustrated in the form of questions and responses from experts.
  • Thumbnail Image
    PublicationOpen Access
    Bortezomib induced pulmonary toxicity: a case report and review of the literature
    (e-Century Publishing Corporation, 2020) Kalyon, Hakan; Özbalak, Murat; Örnek, Serdar; Keske, Şiran; Zeren, Handan; Kurtoğlu, Burçin Sağlam; Tabak, Levent; Çakar, Nahit; Aytekin, Saide; Bölükbaşı, Yasemin; Ferhanoğlu, Ahmet Burhan; Faculty Member; Faculty Member; Doctor; Faculty Member; Faculty Member; School of Medicine; Koç University Hospital; N/A; N/A; 198906; N/A; 216814; 18320
    Bortezomib is widely used in the treatment of Multiple Myeloma. While the most common side effects are neurological and gastrointestinal related complications, severe pulmonary problems are rarely described. The present case is a 72-year old male with multiple myeloma, who received Lenalidomide, Bortezomib, and Dexamethasone (RVD) combination regimen. He underwent 30 Gy palliative radiotherapy to the thoracic 5-9 and lumbar L1-3 vertebra due to pain and fracture risk. During the third cycle, he was admitted to hospital with dyspnea and dizziness. The thoracic CT revealed bilateral pleural effusions, a diffuse reticular pattern on the parenchyma, and ground-glass opacities that were compatible with drug-induced lung injury. The microbiological and molecular analysis excluded infectious disease, and lung biopsy confirmed the diagnosis of Bortezomib Lung Injury. The time from the first dose of Bortezomib to the lung injury was 57 days, and it was five days from the last dose of Bortezomib. His symptoms were refractory to IV steroids and supportive care. Our patient was lost despite steroids and intensive care support. Even Bortezomib induced lung injury is a rare adverse effect, based on high mortality rate, we would like to emphasize the clinical importance of this clinical scenario in light of the published literature and our presented case.
  • Thumbnail Image
    PublicationOpen Access
    Why we should be more careful using hydroxychloroquine in influenza season?
    (Elsevier, 2020) Çelik, Hülya Gamze; Keske, Şiran; Şener, Ülker; Şahin, Şükrü Taylan; Özyıldırım, Aslı; Tekbaş, Müge; Kapmaz, Mahir; Aytekin, Saide; Aytekin, Vedat; Ergönül, Önder; Doctor; Faculty Member; Faculty Member; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; 110398
    The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11–30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02–28, p = 0.047) were found to be associated with critical QTc prolongation.